课题基金 / 基金详情

ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS

ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS
口服 SP 303 用于治疗艾滋病患者的腹泻
批准号:
6304511
负责人:
Paul R Skolnik
金额:
$4.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-12-01 至 2001-02-28

项目摘要

项目成果

Paul R Skolnik的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Diarrhea is a substantial problem for many HIV-infected persons. The causes of diarrhea in this patient group are many; they include problems with absorption, infections that may cause diarrhea, and side effects of drug that are needed to treat HIV infection or prevent opportunistic illnesses. Methods of decreasing drugs side effects are especially important now that highly active antiretroviral therapy is available that decreases viral load and increases survival. Taking these drugs without interruption is important to decrease the chances of mutations in the HIV genome that might result in drug resistance. SP-303 is an investigational agent that has been effective in decreasing diarrhea in other patient groups. This study will determine the safety and efficacy of this drug for the treatment of diarrhea in patients with AIDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE
  • 批准号:
    7606279
  • 项目类别:
  • 资助金额:
    $0.32万
  • 财政年份:
    2007
  • 负责人:
    Paul R Skolnik
  • 依托单位:
INITIAL THERAPY FOR HIV-I INFECTION (ACTG A5142)
  • 批准号:
    7379486
  • 项目类别:
  • 资助金额:
    $0.11万
  • 财政年份:
    2005
  • 负责人:
    Paul R Skolnik
  • 依托单位:
HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE
  • 批准号:
    7379528
  • 项目类别:
  • 资助金额:
    $0.11万
  • 财政年份:
    2005
  • 负责人:
    Paul R Skolnik
  • 依托单位:
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS IN HIV-1 INF MEN & WOMEN
  • 批准号:
    7379524
  • 项目类别:
  • 资助金额:
    $0.22万
  • 财政年份:
    2005
  • 负责人:
    Paul R Skolnik
  • 依托单位:
海外基金